Author/Authors :
Esmalian Afyouni, Nazgol Water and Electrolytes Research Center - Isfahan University of Medical Sciences, Isfahan, Iran , Halili, Hanieh Water and Electrolytes Research Center - Isfahan University of Medical Sciences, Isfahan, Iran , Moslemi, Fatemeh Water and Electrolytes Research Center - Isfahan University of Medical Sciences, Isfahan, Iran , Nematbakhsh, Mehdi Water and Electrolytes Research Center - Isfahan University of Medical Sciences, Isfahan, Iran , Talebi, Ardeshir Department of Clinical Pathology - Faculty of Medicine - Isfahan University of Medical Sciences, Isfahan, Iran , Shirdavani, Soheila Water and Electrolytes Research Center - Isfahan University of Medical Sciences, Isfahan, Iran , Maleki, Maryam Water and Electrolytes Research Center - Isfahan University of Medical Sciences, Isfahan, Iran
Abstract :
Background: Renal ischemia/reperfusion injury (RIRI) is the most common cause of acute kidney injury. We tested the protective role of endothelin‑1 receptor blocker; bosentan (BOS) in animal model of RIRI in two different genders.
Methods: Male and female Wistar rats were assigned as sham operated (sham), control group (ischemia), and case group (ischemia + BOS) treated with BOS (50 mg/kg) 2 h before bilateral kidney ischemia induced by clamping renal vessels for 45 min followed by 24 h of renal reperfusion.
Results: The RIRI significantly increased the serum levels of blood urea nitrogen and creatinine in both genders (P < 0.05). These values were significantly decreased by BOS in both genders. In male rats, the serum levels of malondialdehyde in the ischemia + BOS group were decreased significantly when compared with ischemia group (P < 0.05).
Conclusions: BOS can be used in both genders to attenuate kidney ischemia injury possibly due to its effect in the renal vascular system.
Keywords :
Bosentan , endothelin , gender , ischemia‑reperfusion , kidney
